One retrospective study on patients with uveal melanoma liver metastasis compared the clinical effectiveness and toxicity of SIRT using yttrium-90 microspheres to a historical control group using systemic chemotherapy. Patients on SIRT both as first-line therapy or following failed systemic chemotherapy - had a statistically significant improvement in median overall survival time compared to those on historical systemic chemotherapy, and this effect was larger in the group of patients who received SIRT as first-line treatment. Most treatment-related side effects on patients with SIRT were mild and self-limited, and were more pronounced in patients with systemic chemotherapy. These findings from limited evidence need to be treated cautiously. There was no relevant evidence found on the cost-effectiveness of radioembolization with yittrium-90 microspheres versus other management options for the management of uveal melanoma liver metastases.